Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial

World News: . []

BASEL Switzerland Dec 06 2018 GLOBE NEWSWIRE -- Axovant Sciences NASDAQ AXON a clinical-stage company developing innovative gene therapies for neurological conditions today announced feedback from a face-to-face pre-IND meeting with the U.S. F...

More news and information about Axovant Sciences Ltd.

Published By:

Globe Newswire: 12:00 GMT Thursday 6th December 2018

Published: .

Search for other references to "axovant" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us